Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

curred clinical site start up costs for our three co-therapy trials in the U.K. and our Phase II sarcoma clinical trial in the U.S. During the nine month period ending September 30, 2006, we incurred direct patient costs in four ongoing clinical trials along with clinical site start up costs associated with our U.S. recurrent malignant glioma and U.K. Phase Ia combination REOLYSIN(R)/radiation therapy trials.

We expect our clinical trial expenses will continue to increase for the remainder of 2007 compared to 2006 as we continue patient enrollment and expand our clinical trial program to include other trial sites and other studies.

Pre-Clinical Trial Expenses and Research Collaborations

2007 2006

$ $

-------------------------------------------------------------------------

Research collaboration expenses 694,315 634,199

Pre-clinical trial expenses 37,130 57,354

-------------------------------------------------------------------------

Pre-clinical trial expenses and

research collaborations 731,445 691,553

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the nine month period ending September 30, 2007, our research collaboration expenses were $694,315 compared to $634,199 for the nine month period ending September 30, 2006. Our research collaboration activity continues to focus on the interaction of the immune system and the reovirus, the use of the reovirus as a co-therapy with existing chemotherapeutics, the use of new RAS active viruses as potential therapeutics, and to investigate new uses of the reovirus as a therapeutic.

For the remainder of 2007, we still ex
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Cayenne Medical, Inc., a privately held ... tissue reconstruction segment, announced the worldwide launch of ... the shoulder and extremities. The SureLock System provides ... method. The unique delivery eliminates manual tensioning that ... anchor displacement (also commonly know as anchor “creep”). ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has ... now comes with a second treatment cup to help prevent ... new cup is thinner on the edges for a softer ... thin and uneven surfaces on the face, neck and décolleté. ... treatment on areas such as the cheeks and neck, or ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... 23, 2010Scientists at the Gladstone Institute of Neurological Disease ... in Alzheimer,s disease (AD) and other neurodegenerative diseases. The ... "We examined a protein called tau that ... Gan, PhD, senior author on the study. "Tau forms ...
... LONDON and SAN FRANCISCO, September 22, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... SINGAPORE, Sept. 23 S*BIO Pte Ltd today ... that will support the continued development of S*BIO,s ... commitment reflects the international investment community,s strong interest ... through clinical development and the quality of our ...
Cached Biology Technology:Gladstone scientists identify strategy to reduce toxic proteins associated with Alzheimer's disease 2Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 2Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 3Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 4Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 5Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 6Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 7Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 8Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 9Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 10S*BIO Announces US$5 Million Investment by Mitsui Ventures 2S*BIO Announces US$5 Million Investment by Mitsui Ventures 3
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... new professorship in tissue engineering to promote innovative ... and the Marine Biological Laboratory, supported by a ... Bell Foundation., The Eugene Bell Professorship in Tissue ... Engineering. That endowed chair holder also will direct ... Center for Regenerative Biology and Tissue Engineering, and ...
(Date:7/11/2014)... Shenzhen, China Researchers from Salk Institute for Biological ... time evaluated the safety and reliability of the ... a new method, TALEN-HDAdV, which could significantly increased ... (hiPSC). This study published online in Cell ... for stem cell-based gene therapy. , The combination ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2New professorship in tissue engineering links molecular engineering, marine biology 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... a common goal: making the invisible visible. Yet artistically ... careers. A new four-year, $1.2 million program led by ... and physics of color into a series of summer ... art-interested students to enter careers in science. , ...
... be heading into the rainforests of Nicaragua to help an endangered ... crops are being threatened by the animals. The animals were ... just two years ago when the MSU team discovered them still ... up of still and video cameras in order to "capture" the ...
... New Rochelle, NY, November 15, 2012Epstein-Barr virus (EBV) is ... serious disease in liver transplant recipients. Molecular tests that ... have value for diagnosing active infection. The benefits of ... EBV-infected transplant patients are evaluated in an article published ...
Cached Biology News:New programs draws young artists into science 2Collaring tapirs to help them survive 2
... is one of several isoprostanes produced from arachidonic ... renal vasoconstrictor in the rat. 8-iso PGE2 inhibits ... of 0.5 and 5 µM, respectively. When infused ... a concentration of 4 mg/kg/min, 8-iso PGE2 decreases ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... offers both high-speed and high-volume versatility ... rotor options, making it ideal for a ... Versatility , High-speed (up to 15,000 ... high-volume (4 x 250mL) swinging bucket rotors ...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: